Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients
NCT05147896
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Diabetes Mellitus, Type 2
Atherosclerosis
Interventions
DRUG:
Semaglutide Oral Tablet
Sponsor
University Medical Centre Ljubljana
Collaborators
[object Object]